Navigation Links
Medical researcher's discovery may explain how certain cancers develop
Date:5/27/2010

A Florida State University College of Medicine researcher has discovered a new interaction between a cell signaling system and a specific gene that may be the cause of B-cell lymphoma. The finding suggests a similar interaction could be occurring during the development of other types of cancer, leading to further understanding of how cancer works and how it might be stopped.

Yoichi Kato, an assistant professor in the Department of Biomedical Sciences, and his lab team found that the gene known in scientific shorthand as BCL6 can inhibit one of the pathways cells use to transmit signals to other cells. Called the Notch signaling pathway, it's an important mechanism for cells to control gene regulation.

"There are very few molecules that we know directly inhibit Notch signaling," Kato said. "So that is why the interaction, and our finding, is very interesting to people in many areas cancer specialists, neuroscientists, and many others."

Kato's team produced a paper outlining the findings that was published in the journal Developmental Cell, and Kato recently presented the paper at an international conference in Cold Spring Harbor, N.Y., for scientists studying early development of vertebrates.

Kato and his researchers have focused on the Notch signaling pathway's role in vertebrate early development. In their study, they found that when BCL6 inhibits the Notch signaling pathway during the early stages of embryo development, the alignment of the embryo's internal organs is affected, which can lead to a congenital disorder.

However, the Notch signaling pathway, which creates the equivalent of a molecular highway across a cell's membrane, is involved in many types of cell-to-cell interaction, including neuron development, stem cell differentiation and apoptosis (programmed cell death).

The fact that BCL6 regulates the Notch signaling pathway could be important for any cellular process where Notch plays a role, including the formation of many cancers. BCL6 is a gene that, when mutated in certain ways, can lead to several types of B-cell lymphoma. B-cell lymphomas, including both Hodgkin's and non-Hodgkin's lymphomas, occur when B-cells, which produce antibodies to fight infections, mutate and become cancerous.

With more study of the interaction between the Notch signaling pathway and the BCL6 gene, scientists may be able to better understand how these cancers form. Kato and his lab plan to further investigate the interaction's role in neural development, as well as how the interaction could affect stem cell formation.


'/>"/>

Contact: Doug Carlson
doug.carlson@med.fsu.edu
850-645-1255
Florida State University
Source:Eurekalert  

Related biology news :

1. UM receives 5th consecutive Howard Hughes Medical Institute grant for science education
2. ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records
3. Scientists use biomedical technique to image marine worm
4. Historic medical conference finds Bolivar may have been poisoned
5. Concord Medical Enters Agreement to Acquire Four Radiotherapy and Diagnostic Imaging Centers in Hebei Province
6. Winner Medical Group inc. Prices Offering of 1,380,000 Shares of Common Stock
7. Depression symptoms increase during medical internship
8. Chronix Biomedicals serum DNA assays monitor disease activity and treatment response in MS
9. Electronic medical records may accelerate genome-driven diagnoses and treatments
10. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
11. UT Southwestern student receives fellowship from Howard Hughes Medical Institute
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medical researcher's discovery may explain how certain cancers develop
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
Breaking Biology News(10 mins):
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
Breaking Biology Technology: